Insider transaction details
Erasca NASDAQ:ERAS Chief Medical Officer Shannon Morris completed two linked transactions on March 4, 2026. Morris exercised options to acquire 20,000 shares of Erasca common stock at an exercise price of $1.70, for a cost basis of $34,000. The same day, Morris sold 20,000 shares of common stock for total proceeds of $300,760. The sale was executed at a weighted-average price of $15.038 per share, with trade prices ranging from $15.00 to $15.10. Following the sale, Morris directly holds zero shares of Erasca common stock.
Plan and vesting
The option exercise and subsequent disposition were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Morris adopted on June 30, 2024. The underlying stock options vest on a monthly schedule beginning February 1, 2024 - the exercise on March 4 reflects that vesting cadence.
Market context
The transactions took place as Erasca shares trade near their 52-week high of $16.00, after the stock produced a substantial gain over the prior year. Separately, an analysis available on InvestingPro lists the stock on a Most Overvalued compilation and notes that the company remained unprofitable over the last twelve months.
Financing and analyst activity
Recent corporate and market developments accompany the insider activity. Erasca completed a public offering that raised approximately $258.8 million by selling 25,875,000 shares of common stock at $10.00 per share. Several equity research firms have adjusted their price targets in light of clinical and financing news: Clear Street raised its target to $20.00 from $11.00 while maintaining a Buy rating and cited a clinical trial agreement with Tango Therapeutics; Guggenheim increased its target to $12.00 from $5.00, pointing to progress on pan-RAS and pan-KRAS programs and the recent financing; H.C. Wainwright moved its target to $15.00 from $11.00 after positive clinical updates from the AURORAS-1 study of ERAS-0015; and Stifel reiterated a Buy rating with a $10.00 target following discussions with company executives.
What this means for investors
The transactions represent a simultaneous option exercise and sale under an established trading plan, executed while the stock trades near recent highs and in the wake of both fresh capital and renewed analyst interest. The InvestingPro analysis flagging the stock as appearing overvalued and the company’s continued lack of profitability over the last twelve months are facts that some market participants may weigh alongside the influx of capital and the clinical program updates referenced by analysts.
Note - The article presents the transaction details, vesting schedule, trading-plan disclosure, financing and analyst updates as reported; it does not infer motives for the insider activity.